Angiotensin-converting enzyme (ACE), an important part of the renin-angiotensin system, is implicated in stimulating the fibrotic processes in the heart, lung, liver and kidney, while an ACE inhibitor (ACEI) promotes physiological tissue repair in these organs. The mechanism is closely related to TGF-β1 pathways. However, the reported effects of applying ACEIs during scar formation are unclear. Hence, we explored the anti-fibrotic effects of an ACEI and the molecular mechanisms involved in a mouse scar model.
Introduction
Cutaneous scar formation is a complex but natural process of dermal healing following lacerations, incisions or tissue loss (Thomas and Somenek, 2012) . Evolution has primed some repair processes to heal quickly, but imperfectly (Stramer et al., 2007) . The predilection for scar formation is affected by a variety of factors (Thomas and Somenek, 2012) . Predisposing factors that increase the likelihood of aberrant healing and result in the formation of hypertrophic scars and keloids have been well documented (Thomas and Somenek, 2012; Kerwin et al., 2014; Balaraman et al., 2015; Martin and Nunan, 2015) . Annually, there are 100 million patients in the developing world who are left with scars after healing, which results in expensive financial burdens on Healthcare Systems (Bayat et al., 2003) . Thus, it is crucial to develop an effective and economical strategy to prevent scarring.
Angiotensin-converting enzyme (ACE), an important part of the renin-angiotensin system (RAS), is responsible for converting angiotensin I into the vasoconstrictor angiotensin II (Ang II) (Bernstein et al., 2013) . Apart from Ang II, ACE also affects substance P (SP), acetyl-N-Ser-AspLys-Pro (AcSDKP), angiotensin 1-7 (Ang 1-7) and other peptides (Bernstein et al., 2013) . From current research the role of RAS has expanded: Ang II has been shown to affect cell proliferation and inflammatory responses, not just blood pressure; tissue fibrosis has been found to be closely associated with local RAS stimulation; Ang II plays an important role in the fibrosis process of heart, kidney, lung and liver, and the mechanism is related to the small mothers against decapentaplegic (Smad) pathway and/or TGF-β-activated kinase 1 (TAK1) pathway (Kim et al., 2009; Choi et al., 2012; Watkins et al., 2012; Wong et al., 2018) . Besides, an ACE inhibitor (ACEI) is a good choice for treating these fibrotic processes (Brilla et al., 2003; Mohammadi-Karakani et al., 2006; Kolesnyk et al., 2010; Ghulam et al., 2011) .
The skin tissue also has a complete RAS system (Steckelings et al., 2004) . This RAS system is activated after skin injury, and is then involved in wound repair and tissue reconstruction. During the formation of a hypertrophic scar, the expression of ACE and Ang II are increased, and the expressions of Ang II type 1 (AT 1 ) and AT 2 receptors upregulated (Morihara et al., 2006; Yahata et al., 2006; Tang et al., 2009) . Hakan et al. (2013) reported that early application of enalapril (an ACEI) can reduce scar formation in a rabbit ear wound model. One case report involving two patients showed that a low-dose of enalapril improved a postsurgical abdominal keloid scar (Iannello et al., 2006) . These results suggest that an ACEI is an ideal treatment for scar management, but these studies were mainly limited to the effect of Ang II, and the understanding of how an ACEI and other bioactive peptides are regulated by it has not been elucidated.
In the proliferative phase of the wound healing process, a significant element that affects scar formation is TGF-β (Cutroneo, 2007) . Although there are three isoforms in the TGF-β family, the development of tissue fibrosis is primarily attributed to TGF-β1 as it is ubiquitously found in mammalian tissues (Biernacka et al., 2011) . The classical signalling pathway for TGF-β1 involves the Smad family (Shi and Massague, 2003) . Upon phosphorylation by TGF-β1 receptors, Smad2 and Smad3 (known as receptor Smads) form heteromeric complexes with co-Smad or Smad4. The Smad2-Smad3-Smad4 complex is then translocated into the nucleus, where it functions as a transcription factor, binding DNA either directly or in association with other DNA proteins (Shi and Massague, 2003; Cutroneo, 2007) . In addition to this, a mostly Smad-independent signalling pathway that mediates the profibrotic effects of TGF-β1 operates via TAK1 (Choi et al., 2012) . TAK1 is involved in TGF-β1-induced type I collagen and fibronectin expression by activating the MAPK kinase 3 (MKK3)-p38 and MKK4-JNK signalling cascades respectively (Choi et al., 2012) . Given that TGF-β1 signal pathways are so closely associated with scar management, we hypothesized that an ACEI might reduce scar formation by modulating TGF-β1-related pathways. Thus, we investigated the underlying mechanism in vitro and in vivo.
First, we used scar models in ACE knockout (KO) and ACE wild-type (WT) mice to confirm the effect of ACEI. Then, since the fibroblasts are the ultimate effector cells of scar formation (Ghahary et al., 1996) and Heemskerk et al. had demonstrated the presence of ACE in a fibroblast cell model (Heemskerk et al., 1999) , we used mouse fibroblasts cultured in different concentrations of ACEI to evaluate the level of fibrosis and the TGF-β1 signalling. To further confirm our data in vivo, we explored the effect of ACEI in murine models of scar formation.
Methods

Ethics
All experiments and protocols are in accordance with the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health (NIH Publication No. 85-23, Revised 1996) and performed under the authorization of the Institutional Animal Care and Use Committee of Cedars-Sinai Medical Center (Study ID: IACUC004978). Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010) .
In order to study the role of ACEI, we chose the ACE KO mice and ACE WT mice. Male mice (8-12 weeks old, average weight 25 g) were used. In ACE KO mice, both N-terminal and C-terminal domains were knocked out. It is a total ACE KO mouse model, which means that there is no ACE expressed in any of the cells and tissues of these ACE KO mice (Esther et al., 1996) . ACE WT mice have normal circulating levels of ACE. Each line was backcrossed to C57BL/6 (C57) for 10 or more generations. C57BL/6 mice were from the Jackson Laboratory (USA). During the experiments, the animals were housed in Cedars-Sinai Medical Center, maintained under controlled environmental conditions (12 h light-dark cycle, temperature approximately 25°C) and provided with food and water ad libitum. The authors declare that the data supporting the findings of this study are available within the article.
Mice and cells
Randomization was accomplished as follows. Animals were first assigned to a designated group and weighed. A total of 24 ACE WT mice were divided into three different weight groups (eight animals per group). Then, each mouse was assigned a temporary random number within the weight range group, and four other empty cages were given a numerical designation. For each group, a cage was selected randomly from the pool of all cages. Two mice were removed from each weight range group and given their permanent numerical designation in the cages. Then, the cages were randomized within the experimental group. Ramipril (the first group; 10 mg·kg À1 bodyweight day À1 ; Sigma-Aldrich, St. 
Wound model in mice
The wound was produced on the back of all animals as previously described (Galeano et al., 2008) , with a few changes. Briefly, the mouse was anaesthetized with inhalational isoflurane (1-2% in oxygen) using a rodent anaesthesia machine. After the hair was removed, carprofen (5 mg·kg À1 of a 1.0 mg·mL À1 solution) was injected s.c. Using sterile ophthalmic scissors, a thin rectangle of skin (1.5 cm × 0.2 cm) parallel to but 0.4 cm away from midline was excised on both sides of the dorsum. Thus, each mouse had two small sections of skin removed. The incision was through the dermis and subcutaneous fascia to expose the underlying muscle (which was not cut). Wound care with 70% ethanol was performed on days 2 and 4 post-surgery, and the width of the wounds or scars was measured by a sliding calliper after the surgery. Fourteen days after the operation, the mice were anaesthetized with inhalational isoflurane and killed by cervical dislocation. The scars were harvested for analysis. The experimenters were blinded to the treatments given to the animals and to the biochemical and histological analyses and data analyses.
Histopathological examination
Scar samples surrounded by a margin of unwounded skin were collected at day 14 after injury (n = 12 wounds in six mice from each group). The wounds were divided in half in the least-healed portion. They were then fixed overnight at 4°C in 60% methanol, 30% chloroform and 10% acetic acid. The tissues were processed through a graded series of ethanol and embedded in paraffin blocks. Tissue sections were stained with haematoxylin-eosin or Masson's trichrome to visualize neotissue formation, collagen deposition and the amount of neovasculature. The slices were scanned by Aperio Scanscope AT Turbo (Leica, USA), and photos were taken using Aperio ImageScope v12.1 software (Leica, USA). The actual measurements of widths and areas were carried out with ImageJ version 1.49 for Windows (National Institute of Health, USA).
Flow cytometry analysis
APC-conjugated anti-TGF-β1 (TW7-16B4) was from BioLegend (San Diego, CA, USA). Alexa Fluor® 647-conjugated anti-p-Smad2/3 (O72-670) was from BD Pharmingen (San Jose, CA, USA). To stain intracellular tSmad2/3 and t-TAK1, we used rabbit polyclonal antibodies to t-Smad2/3 or t-TAK1 (Cell Signaling Technology, Danvers, MA, USA) followed by PE-conjugated goat anti-rabbit IgG (SouthernBiotech, Birmingham, AL, USA) with fixation and permeabilization buffers from eBioscience. The events which are recorded for flow cytometry are 1 × 10 4 . The stained samples were analysed on a Beckman Coulter CyAn ADP (Beckman Coulter, Fullerton, CA, USA), and data were analysed with FlowJo software (Tree Star, Inc., Ashland, OR, USA). The number of biological repeats was at least three in the flow cytometry experiments.
Western blot analysis
Scar tissues or fibroblast cells (WT and KO cells) were homogenized in RIPA buffer (Thermo Scientific, Scotts Valley, CA, USA) mixed with a protease inhibitor cocktail (Thermo Scientific), loaded on a 4-12% gradient bis-Tris gel for electrophoresis (Invitrogen, Carlsbad, CA, USA) and transferred electrophoretically to a PVDF membrane using a conventional method, as described previously (Tan et al., 2011) .
The detection in cells. The membrane was blocked (Odyssey, Pomona, CA, USA) and incubated with a rabbit anti-p-Smad2 The results were normalized to the respective expression level of α-tubulin or β-actin.
Real-time RT-PCR
To analyse the mRNA levels in the scar tissues or fibroblast cells (WT and KO), total RNA was extracted using RNeasy Mini Plus kits (Qiagen, Valencia, CA, USA). The purified RNA (200 ng) was reverse transcribed using a high-capacity iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, USA). The expression levels of TGF-β1 (Mm01178820_m1), Smad2/3 (Mm01170760_m1), TAK1 (Dm01822778_g1), collagen I (Mm00801666_g1) and collagen III (Mm01254476_m1) and GAPDH (Mm99999915_g1) mRNAs (the primers were bought from Applied Biosystems) were analysed with quantitative real-time RT-PCR using an ABI OneStepPlus™ Real-Time PCR System (Applied Biosystems, Carlsbad, CA, USA). The PCR conditions were 95°C for 30 s, followed by 40 cycles of 95°C for 30 s and 60°C for 10 s, and elongation at 72°C for 15 s. The results from five or six independent vials were used to determine the relative expression levels of the target genes, which were normalized against the expression level of GAPDH.
Immunohistochemistry
Paraffin-embedded sections were subjected to immunohistochemical assays. Briefly, the sections were deparaffinized with xylene, rehydrated through a graded series of ethanol to water and then incubated in blocking solution (PBS + 1% BSA) at room temperature for 1 h. Sections were then incubated overnight at 4°C with one of the following primary antibodies: rabbit polyclonal anti-angiotensin II (1:500 dilution; Phoenix Pharmaceuticals, Burlingame, CA, USA; Cat# H-002-12), rat monoclonal antibody anti-substance P (dilution 1:200; GeneTex, Irvine, CA, USA; Cat# GTX72999) or rabbit polyclonal antibody anti-angiotensin 1-7 (1:300 dilution; Phoenix Pharmaceuticals, Burlingame, CA, USA; Cat# H-002-24). All antibodies were diluted with blocking solution. Immunostaining was carried out with an avidin-biotin-peroxidase complex kit (DAB Peroxidase Substrate Kit, Vector Laboratories, Burlingame, CA, USA) and counterstaining with haematoxylin. The tissue slices were scanned by Aperio Scanscope AT Turbo (Leica, USA), the photos were taken at 20× in the Aperio ImageScope v12.1 software (Leica, USA), and the measurements were carried out with ImageJ version 1.49 for Windows (National Institute of Health, USA).
ELISA
ACE buffer was made in our laboratory: 150 mM NaCl, 25 μM ZnCl 2 , 50 mM HEPES (pH 7.4) and 0.5% Triton X-100. Scar tissues were washed and homogenized in ice-cold ACE buffer (pH = 7.4) to obtain a 20% homogenate (w . v -1 ), which was then centrifuged for 15 min at 3000× g and 4°C. The supernatant obtained was used for measuring TGF-β1 by the sandwich ELISA kits according to the manufacturers' instructions. The capture antibody clones eBioTB2F (anti-TGF-β1; Cat# 14-9943) and detection antibody eBio16TFB (anti-TGF-β1; Cat# 13-9923) were from eBioscience; the recombinant human TGF-β1, used as the standard, was from Peprotech (Rocky Hill, NJ, USA; Cat# 100-21C). AcSDKP was detected by the AcSDKP enzyme immunoassay kit (ALPCO; 32-5881) according to the manufacturer's instructions.
Statistical analysis
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) and its update (Curtis et al., 2018 
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www. guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., 2018) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2017a,b) .
Results
ACEI reduces scar formation and TGF-β1 expression
To figure out the connection be between ACEI and scar formation, ACE KO mice (Esther et al., 1996) (no ACE expression) and WT mice (normal ACE expression) were used to created mouse scar models. A section of skin was surgically removed from the back of WT and KO mice ( Figure 1A ). With the design in the methods, WT mice were randomly grouped as ramipril (ACEI), losartan (angiotensin receptor blocker) or hydralazine (another type of blood pressure lowering agent) group. Control group only received vehicle (water), which was used to control for unwanted sources of variation. In addition, a group of KO mice was treated identically to the WT animals, although no drug was administered.
The wound/scar width of all five groups was analysed throughout the healing process ( Figure 1B) . The results showed that the width of KO and ramipril groups narrowed beginning on day 7 and became significant on day 12 after injury. Interestingly, the width of losartan group seemed to be wider than the other groups at first. However, similar to the KO and ramipril groups, it showed positive result at the 14th postoperative day. The width of hydralazine and WT groups narrowed gradually, though it was in a slower pace. All wounds in these groups were completely crusted over a 7 day period, more than 80% of the scab fell off in 10 days, and the scar changes were observed in 10-14 days. After that, the animals were killed ( Figure 1C ). Microscopic examination on the final day revealed that scars in KO, ramipril and losartan groups not only had narrower widths but also showed enhanced re-epithelialization, organized granulation tissue formation and neovascularization (Figure 2A ). Masson staining clearly showed that the KO, ramipril and losartan groups had loosely arranged collagen fibres, and fewer fibroblasts, while the hydralazine and blank control groups had dense, irregular collagen fibres and more fibroblasts ( Figure 2B ). The real scar width and real area were also revealed by histological examination ( Figure 2C ). Given the prominent role of TGF-β1 in scar formation (Ikushima and Miyazono, 2011) , we also examined the effect of ACEI on the expression of TGF-β1. The sandwich ELISA showed that the expression of TGF-β1 was significantly down-regulated in scar tissue of KO, ramipril and losartan groups ( Figure 2D ). These findings indicate that ACEI improved scar formation and reduced TGF-β1 expression.
ACEI inhibits fibroblasts proliferation, TGF-β1 and collagen expression
Fibroblasts provide many regulatory mediators to the microenvironment and thereby contribute to maintenance of wound healing and scar formation (Eckes et al., 2014; Schmidt et al., 2015) . We therefore investigated the effect of different ACEI levels on the proliferation of murine fibroblasts. We chose ramipril for the in vivo experiments because it has a relatively longer half-life than other ACEIs, whereas we used lisinopril to treat the cultured cells because it is more soluble in water than other ACEIs.
Cell proliferation was detected by CCK-8. The ACE KO and ACE WT fibroblasts (5 × 10 3 cells for each well) were seeded in 96-well plates with various concentrations (0, 1, 10 and 100 μM) of lisinopril and cultured for 48 h before testing. The results detected showed that proliferation of WT cells with lisnopril at a concentration of 10 and 100 μM was significantly inhibited, as well as the KO cells ( Figure 3A) . TGF-β1 up-regulation has been implicated in scar formation (Campaner et al., 2006) ; thus, in parallel,
Figure 1
Scar formation in a murine model of full-thickness skin wounds. (A) Representative mouse scar model. (B) Statistical analysis of wound/scar width in five groups (n = 12 wounds in six mice each group), the width of the wounds or scars, was measured by the sliding calliper after the surgery. All results given as mean ± SEM. *P < 0.05 as compared to the blank group, respectively, by least significant difference and Student-Newman-Keuls tests. (C) Representative mouse scar of KO group (K), ramipril group (R), losartan group (L), hydralazine group (H) and blank control group (B) on the 14th day postoperatively. cells received 0.5 ng·mL À1 TGF-β1 in order to simulate the traumatic stimulus. In these groups, cell proliferation decreased with the down-regulation of ACE, and the significant results started at a concentration of 10 μM lisnopril ( Figure 3B ). To further confirm the efficacy of lisnopril at a concentration of 10 μM, TGF-β1 detection of ACE WT cells with or without 10 μM lisinopril and ACE KO cells was performed. The flow cytometry result showed that TGF-β1 of the ACE WT cells decreased significantly with the presence of 10 μM lisinopril ( Figure 3C and Supporting Information Figure S1 ). Excessive accumulation of collagen is a key feature of fibrosis, as well as in scar formation (Kim et al., 2010) . Thus, we also detected the total collagen in different ACEI levels by Sirius Red Collagen Detection Kit ( Figure 3D ). Irrespective of the addition of TGF-β1, the secretion of total collagen in WT cells was highest, followed by WT cells with 10 μM lisinopril, and finally KO cells. This finding obviously showed that applying ACEI depressed the total collagen secretion.
ACEI inhibits Smad2/3 and TAK1 pathways in vitro
To further assess the mechanism underlying ACE-related down-regulation of TGF-β1 during scar formation, we detected Smad2/3 and TAK1 pathways in vitro.
We used flow cytometry to detect the expression of total Smad2/3 (t-Smad2/3) and total TAK1 (t-TAK1), which are two significant transcription factors in TGF-β1 signalling (Yamaguchi et al., 1995; Dabiri et al., 2008) . The number of cells counted in five independent biological repeats. The result showed that t-Smad2/3 and t-TAK1 in the ACE KO cells decreased significantly compared with those in ACE WT cells, while there was no difference between WT cells and WT cells with 10 μM lisinopril ( Figure 4A ,B and Supporting Information Figures S2 and S3) . The real-time RT-PCR detection showed that the mRNA expression of t-Smad2/3 and t-TAK1 were also lower in KO cells, as well as the mRNA expression quantity of TGF-β1, collagen I and III ( Figure 4C) .
Further, Phospho-Smad2/3 (p-Smad2/3) and Phospho-TAK1 (p-TAK1) were determined by western blot analysis. The green bars (A) are used to mark the scales of scar, the white bars = 500 μm (A) /100 μm (B). In each composite picture, K represents KO group, R represents ramipril group, L represents losartan group, H represents hydralazine group and B represents blank control group. (C) The actual (real) scar area and width were determined in each group of mice (n = 12 wounds in six mice for each group). The results are given as mean ± SEM. *P < 0.05 as compared to the blank group respectively, by least significant difference (LSD) and Student-Newman-Keuls (SNK) tests (D) The content of TGF-β1 in 1 g of scar tissue (n = 12 wounds in six mice for each group). All results are given as mean ± SEM. *P < 0.05 as compared to the blank group, respectively, by LSD and SNK tests.
These demonstrated that treatment with lisinopril reduced the amount of p-Smad2/3 and p-TAK1 as compared to equivalent cells not treated with lisinopril ( Figure 5A ). Interestingly, p-Smad2/3 could not be seen in western blot analysis, without the stimulation of TGF-β1. However, the flow cytometry results showed that it did existed ( Figure 5B and Supporting Information Figure S4 ). Notably, when the cells were stimulated in 2 ng·mL À1 TGF-β1
for 30 min, the results could be well demonstrated ( Figure 5C ).
ACEI inhibits Smad2/3 and TAK1 pathways in vivo
On the basis of the underlying ACE-related down-regulation of TGF-β1 in murine fibroblasts, we next sought to determine the potential mechanism in mouse scar model. As we wanted to focus on the effects of ACEI in scar management, this time, there were only four groups (n = 12 wounds in six mice each group): ramipril group, hydralazine group, blank group and KO group. All wounds in these groups were completely closed on the 14th postoperative day. Then the animals were killed, and scar tissues were collected.
Consistent with our in vitro data, western blot analysis demonstrated that the amount of p-Smad2/3 and p-TAK1 in scar tissue of KO group and ramipril group was statistically lower than hydralazine group and WT (blank control) group, as well as the expression of α-SMA, collagen I and III ( Figure 6A ). We also confirmed that the mRNA expression quantity of TGF-β1, Smad3, TAK1, collagen I and III in scar tissue of ACE KO mice was statistically lower than ACE WT mice ( Figure 6B ).
ACEI influences ACE-related peptides in vivo
ACE is an important role in many physiological and biochemical processes. One of the reasons probably is that it influences many peptides. We wanted to determine whether these ACE-related peptides are also involved in scar formation. Thus, the peptides Ang II, SP and Ang 1-7 were assessed by immunohistochemistry (Figure 7A-D) . Not surprisingly, animals that were ACE KO or treated with ramipril had significantly lower scar tissue concentrations of Ang II. In contrast, these same animals had elevated tissue levels of SP and Ang 1-7. Since the antibody of AcSDKP was not available at that time, it was measured by ELISA (Figure 8) , and the results in KO and ramipril groups were statistically higher than the ACEI for scar formation hydralazine and blank groups. Thus, these data underscore the crucial connection between ACEI and ACE-related peptides in scar formation.
Discussion
Scar formation characterized by persistent alteration of the normal structure of skin following injury is the unavoidable outcome in adult mammal wound healing (Qi et al., 2014) . Overproliferation of fibroblasts and overproduction of extracellular matrix components lead to deleterious consequences (Pohlers et al., 2009; Yuan et al., 2013) . Abnormal TGF-β1 signalling is implicated in an increasing number of fibrotic and inflammatory pathologies (Santibanez et al., 2011) . Our study defines what we believe to be a previously undescribed property of ACEI that, via the reduction of fibroblasts and extracellular matrix components, mediated a so far unknown switch from a high fibrosis-promoting to a low anti-fibrotic TGF-β1 expression. In addition, both Smad2/3 and TAK1 pathways were involved in the regulation of TGF-β1 signalling at scar sites. The combined extracellular matrix components changes and the switch to a favourable TGF-β1 content eventually resulted in improved wound healing and significantly reduced scar formation in murine full-thickness wounds.
As there are unique features in human scars, animal models for the development of new therapeutic interventions are limited. Instead of choosing a rabbit ear wounding model (Hakan et al., 2013) , we used murine full-thickness wounds including the circumscribed excision of the panniculus carnosus. Mice have been widely used as animal models to study the mechanism of wound healing and scar formation (Davidson, 1998) . Despite some differences between murine and human wound healing (Wong et al., 2011) , similar to human wound healing by secondary intention, these wounds heal via myofibroblast-driven contraction, granulation tissue formation, subsequent collagen deposition and scar formation (Peters et al., 2005; Sindrilaru et al., 2009; Qi et al., 2014) . Previously, it was believed that
Figure 4
ACEI influences Smad2/3 and TAK1 in vitro. (A, B) The detection of t-Smad2/3 (A) and t-TAK1 (B) in ACE WT and ACE KO cells without or with 10 μM lisinopril (n = 5). Error bars depict the mean ± SEM. *P < 0.05 by least significant difference and Student-Newman-Keuls tests. (C) The mRNA expression of TGF-β1, Smad3, TAK1, collagen I and III in fibroblasts from WT and KO mice and normalized to GAPDH (n = 5). Error bars depict the SEM. *P < 0.05 by t-tests.
wound healing in mice mostly resulted from the wound contraction, so the prognosis was not obvious in scar formation. But we improved this model: we created the wounds in animal back with a certain tension in the defect, which could cause obvious scar formation. The scar model has been used for many times in our previous study and good results have been obtained. On the other hand, most cells involve in wound healing, including lymphocytes, neutrophils, macrophages and fibroblasts. Fibroblasts, as the major mesenchymal cell type in connective tissue, are recruited to the injured site and deposit collagen and elastic fibres (Kalluri and Zeisberg, 2006) , thereby contribute to maintenance of wound healing and scar formation (Eckes et al., 2014; Schmidt et al., 2015) . Thus, we chose mice fibroblasts to perform the in vitro studies. Here, we provide evidence that myofibroblast-dependent scar formation is affected by ACEI and ACEI-related TGF-β1 qualifies as a significant role in fibrosis-reduced tissue repair. TGF-β1 is almost ubiquitously found in mammalian tissues (Biernacka et al., 2011) . In most situations, TGF-β1 promotes wound repair, tissue regeneration and anti-inflammatory effects and thereby exerts cytoprotective effects to mitigate tissue injury (Singer and Clark, 1999) . However, chronically dysregulated expression and actions of TGF-β1 lead to the pathogenic fibrosis in response to tissue injury (Biernacka et al., 2011; Choi et al., 2012) . Our study showed that scars of WT mice treated with ramipril or ACE KO mice had improved collagen deposition and lower TGF-β1 content, which indicates that downregulating ACE in scar can reduce TGF-β1 expression directly or indirectly. Although the losartan group had the similar results at the final day, as we wanted to focus on the effect of ACEI, the further studies were not involved. Interestingly, recent study reported that applying valsartan (one of angiotensin receptor blockers) topically was a favourable treatment for chronic diabetic wounds (Abadir et al., 2018) . Future studies should elucidate the effects of angiotensin receptor blockers on scar formation.
Smad2/3 and TAK1 are two key downstream effectors in the propagation of TGF-β1 signalling. Smad2/3 and TAK1 pathways share many overlapping downstream targets, exhibit crosstalk and utilize positive and negative feedback to regulate pathological process (Watkins et al., 2012; Kaminska et al., 2013) . TAK1 and Smad2/3 involvement in scleroderma and wound healing is known (Shi-wen et al., 2009; Jiang et al., 2016) . Our study in vitro and in vivo showed that fibroblasts and scars of WT mice treated with ACEI or KO mice had lower p-Smad2/3 and p-TAK1 expression, demonstrating that ACEI suppresses the phosphorylation of Smad2/3 and TAK1. The detection of t-Smad2/3 and t-TAK1 in WT fibroblasts treated with lisinopril showed that it was no difference with that in WT cells untreated, while the content in KO cells showed significantly lower. Therefore, we speculate that ACEI inhibits the phosphorylation but not the total content of Smad2/3 and TAK1. The results represent the mean ± SEM of five independent experiments and were normalized to α-tublin (n = 5). *P < 0.05 by LSD and SNK tests.
ACE, as an important biochemical enzyme, can regulate Ang II, SP, AcSDKP, Ang 1-7, enkephalin, neurotensin and other peptides (Bernstein et al., 2013) . Some of these peptides related with fibrosis were assessed in our study. Reduction of Ang II was shown to attenuate the progression of hepatic fibrosis. Our finding showed lower content in scar tissue of WT mice treated with ramipril or ACE KO mice, indicating that it might be one of the reasons for better results in these groups. Ang 1-7 and AcSDKP were defined as two protective roles for fibrosis. It was documented that Ang 1-7 attenuated skeletal muscle fibrosis in a mouse model (Willey et al., 2016) and AcSDKP reduced bleomycin-induced lung fibrosis (Li et al., 2010) . In the groups with better results of our study, Ang 1-7 and AcSDKP were higher, which also can partly explain the better outcome. SP was reported that it could promote intestinal fibrogenesis (Koon et al., 2010) . However, our study showed higher content of SP in groups with better results (WT mice treated with ramipril and KO mice groups). Perhaps it is because other positive effects worked stronger than the negative effect of SP. Taken together, our data inspire the notion that ACEI and ACE-related peptides had close connection with scar formation.
Our study also provides a new sight in scar management. TGF-β signalling has been considered as a potential therapeutic target for the treatment of fibrotic diseases (Gordon and Blobe, 2008; Itoh and Itoh, 2011) . Three strategies have been
Figure 6
ACEI inhibits p-Smad2/3 and p-TAK1 pathways in vivo. (A) Western blot analysis of p-Smad2/3, p-TAK1, α-SMA, collagen I and III in scar tissue at the 14th postoperative day and normalized to β-actin (n = 12 wounds from six mice in each group). K or KO: ACE KO mice; R or Ramipril: WT mice treated with ramipril; H or Hydralazine: WT mice treated with hydralazine; B or Blank: WT mice without other treatment. Results given as mean-± SEM. *P < 0.05 as compared to the blank group, respectively, by least significant difference and Student-Newman-Keuls tests. (B) The mRNA expression of TGF-β1, Smad3, TAK1, collagen I and III in scar tissue at the 14th postoperative day, normalized to GAPDH (n = 12 wounds from six mice in each group). *P < 0.05 by t-tests. Error bars depict the SEM.
developed to inhibit TGF-β signalling, including antisense nucleotides, monoclonal antibodies and small-molecule inhibitors of the TGF-β receptor (Bonafoux and Lee, 2009 ). It should be noticed that there are three TGF-β ligand isoforms and three receptors. It appears difficult to adequately block TGF-β signalling by targeting a single ligand or receptor. Thus, therapies in fibrosis targeting TGF-β only yielded disappointing results in some small clinical trials (Varga and Pasche, 2008) . TGF-β1 was considered as the most essential target for scar management, as it supports excessive and unorganized collagen deposition (Ignotz and Massague, 1986) . Although reducing the expression of TGF-β1 by gene transfection or antibodies was documented in experiments (Qi et al., 2014; Karimizadeh et al., 2015) , there is no product available for routine use. Besides, TGF-β1 regulates the expression of multiple genes related to fibrosis via both Smad-dependent and Smad-independent pathways. Therefore, simultaneous inhibition of Smad and TAK1 by ACEI perhaps is a promising strategy to block TGF-β1 signal transduction. As ACEIs are cheap and easily available, if further analysis confirms their efficiency in human, they can be used in the clinic, effectively and economically.
Patients who are already on an ACEI for hypertension or other cardiovascular conditions would be benefit from it,
Figure 7
ACEI influences related peptides in vivo. (A, B, C) Representative figures for effects on Ang II (A), SP (B) and Ang 1-7 (C) expression in scar tissue obtained at the 14th day (immunohistochemistry staining). The white bars = 100 μm. In each composite picture, K represents KO group, R represents ramipril group, H represents hydralazine group and B represents blank control group. (D) Ang II, SP and Ang 1-7 expression in scar tissue obtained at the 14th day (n = 12 wounds from six mice in each group). Results given as mean ± SEM. *P < 0.05 as compared to the blank group, respectively, by least significant difference and Student-Newman-Keuls tests. and this would have been a good indication for ACEIs. Since wound healing could be better achieved in both mice and pigs by giving valsartan topically (Abadir et al., 2018) , we also should explore the topical application for scar management, like transdermal administration. Further, a comparison between systemic and topical administration of ACEI will be needed in addition to further experiments in order to clarify if ACEI may also represent a novel therapeutic approach to other dermatological disorders in humans.
Conclusion
In conclusion, our findings provide powerful insight into a facet of ACEI that affects the TGF-β1 content in scar formation, regulates both Smad and TAK1 pathways and influences related peptides. ACEIs, by reducing Smad and TAK1 phosphorylation, hold promise for the development of antifibrotic therapies.
Figure 8
The concentration of AcSDKP in 1 g of scar tissue tested by ELISA (n = 12 wounds from six mice in each group). Results given as mean-± SEM. *P < 0.05 as compared to the blank group, respectively, by least significant difference and Student-Newman-Keuls tests.
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